1617Safety, Tolerability, and Antiretroviral Activity of Raltegravir in HIV-1 Infected Russian Children and Adolescents – a 24 Week Study
نویسندگان
چکیده
HIV-1 Infected Russian Children and Adolescents – a 24 Week Study Hedy Teppler, MD; Andrey Shuldyakov, MD; Natalia Gankina, PhD; Valeriy Kulagin, PhD; Firaya Nagimova, PhD; Tatiana Shimonova, PhD; Dmitriy Sonin, PhD; Vladimir Sotnikov, MD; Natalia Zakharova, MD; Brenda Homony, MS; Deng Wang, PhD; Grigoriy Moshkovich, MD; Merck and Co., Inc., Whitehouse Station, NJ; Regional Center for Prevention and Control of AIDS and Infectious Diseases, Saratov, Russia; Regional Center for Prevention and Control of AIDS and Infectious Diseases, Krasnoyarsk, Russia; Clinical Center for Prevention and Control of AIDS and Infectious Diseases, Krasnodar, Russia; Republican Center for Prevention and Control of AIDS and Infectious Diseases, Kazan, Russia; Infectious Clinical Hospital #2 of Moscow City Healthcare Department, Moscow, Russia; Regional Clinical Dermatovenerologic Dispensary, Ryazan, Russia; Regional Center for Prophylaxis and Control of AIDS and Infectious Diseases, Kaluga, Russia; Centre for Prophylaxis and Control of AIDS and Infectious Diseases, St. Petersburg, Russia; Regional Centre for Prevention and Control of AIDS and Infectious Diseases, Nizhniy Novgorod, Russia
منابع مشابه
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
BACKGROUND In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. METHODS SPRING-2 is an ongoing phase 3, randomised, double-blind, active-controlled, non-inferiority study in treatment-naive adults infected with HI...
متن کاملMetabolic Abnormalities in HIV-Positive Patients Receiving Highly Active Antiretroviral Therapy
Background and Objective: Dyslipidemia has become a common problem in human immunodeficiency virus (HIV) disease, especially in patients on combination antiretroviral therapy. In this study we aimed to determine the prevalence of dyslipidemia and metabolic abnormalities in 2 groups of HIV infected patients receiving highly activ...
متن کاملRaltegravir for HIV-1 infected children and adolescents: efficacy, safety, and pharmacokinetics
Raltegravir was the first HIV integrase strand-transfer inhibitor to be approved by the US FDA, in October 2007, for the treatment of HIV-1 infection in combination with other antiretroviral agents. Raltegravir can be used in treatment-naïve and -experienced patients, as well as for the treatment of multidrug-resistant infection. Raltegravir exists in two formulations: a film-coated tablet admi...
متن کاملVirologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-week results of the CHEER study.
OBJECTIVES To determine the safety and efficacy of changing enfuvirtide to raltegravir in HIV-1-infected patients with HIV-1 RNA below the level of quantification for at least 6 months on an enfuvirtide-containing antiretroviral regimen. DESIGN Prospective, nonrandomized, historical control study. METHODS Patients were recruited from 11 Kaiser Permanente HIV clinics in California. Those pat...
متن کاملRaltegravir with optimized background therapy for resistant HIV-1 infection.
BACKGROUND Raltegravir (MK-0518) is an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase active against HIV-1 susceptible or resistant to older antiretroviral drugs. METHODS We conducted two identical trials in different geographic regions to evaluate the safety and efficacy of raltegravir, as compared with placebo, in combination with optimized background therapy, in patient...
متن کامل